Titre : Granulomatose avec polyangéite

Granulomatose avec polyangéite : Questions médicales fréquentes

Termes MeSH sélectionnés :

Workforce
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Granulomatose avec polyangéite : Questions médicales les plus fréquentes", "headline": "Granulomatose avec polyangéite : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Granulomatose avec polyangéite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Granulomatose avec polyangéite" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "url": "https://questionsmedicales.fr/mesh/D056648", "about": { "@type": "MedicalCondition", "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "code": { "@type": "MedicalCode", "code": "D056648", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.111.193" } } }, "about": { "@type": "MedicalCondition", "name": "Granulomatose avec polyangéite", "alternateName": "Granulomatosis with Polyangiitis", "code": { "@type": "MedicalCode", "code": "D014890", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Benjamin Terrier", "url": "https://questionsmedicales.fr/author/Benjamin%20Terrier", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France benjamin.terrier@aphp.fr." } }, { "@type": "Person", "name": "Xavier Puéchal", "url": "https://questionsmedicales.fr/author/Xavier%20Pu%C3%A9chal", "affiliation": { "@type": "Organization", "name": "Centre de Référence des Maladies Systémiques Auto-immunes rares, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@aphp.fr." } }, { "@type": "Person", "name": "Christian Pagnoux", "url": "https://questionsmedicales.fr/author/Christian%20Pagnoux", "affiliation": { "@type": "Organization", "name": "Vasculitis Clinic, Division of Rheumatology, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada." } }, { "@type": "Person", "name": "Roman Yatsyshyn", "url": "https://questionsmedicales.fr/author/Roman%20Yatsyshyn", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine." } }, { "@type": "Person", "name": "Olena Zimba", "url": "https://questionsmedicales.fr/author/Olena%20Zimba", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Profile of the Oncology Physician Workforce and the Characteristics of Attrition.", "datePublished": "2023-05-15", "url": "https://questionsmedicales.fr/article/37186885", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1200/OP.22.00830" } }, { "@type": "ScholarlyArticle", "name": "A national survey of the radiotherapy dosimetrist workforce in the UK.", "datePublished": "2022-09-26", "url": "https://questionsmedicales.fr/article/36063424", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1259/bjr.20220459" } }, { "@type": "ScholarlyArticle", "name": "Telebehavioral Health: Workforce, Access, and Future Implications.", "datePublished": "2022-05-14", "url": "https://questionsmedicales.fr/article/35680247", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.psc.2022.03.008" } }, { "@type": "ScholarlyArticle", "name": "Impact of federalization for health financing and workforce in Nepal.", "datePublished": "2023-06-08", "url": "https://questionsmedicales.fr/article/37291678", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41256-023-00304-3" } }, { "@type": "ScholarlyArticle", "name": "Steps toward a resilient future nurse workforce.", "datePublished": "2023-04-14", "url": "https://questionsmedicales.fr/article/37053471", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1515/ijnes-2022-0057" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Maladies auto-immunes", "item": "https://questionsmedicales.fr/mesh/D001327" }, { "@type": "ListItem", "position": 4, "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "item": "https://questionsmedicales.fr/mesh/D056648" }, { "@type": "ListItem", "position": 5, "name": "Granulomatose avec polyangéite", "item": "https://questionsmedicales.fr/mesh/D014890" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Granulomatose avec polyangéite - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Granulomatose avec polyangéite", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Granulomatose avec polyangéite", "description": "Comment diagnostiquer la granulomatose avec polyangéite ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nQuel rôle joue la biopsie dans le diagnostic ?\nQuels symptômes cliniques orientent vers cette maladie ?\nComment les examens d'imagerie aident-ils au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Workforce&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Granulomatose avec polyangéite", "description": "Quels sont les symptômes courants de cette maladie ?\nLa granulomatose affecte-t-elle les voies respiratoires ?\nQuels problèmes rénaux peuvent survenir ?\nY a-t-il des manifestations cutanées ?\nLes symptômes varient-ils d'un patient à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Workforce&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Granulomatose avec polyangéite", "description": "Peut-on prévenir la granulomatose avec polyangéite ?\nComment éviter les complications ?\nLes vaccinations sont-elles recommandées ?\nY a-t-il des conseils de mode de vie à suivre ?\nLes patients doivent-ils éviter certains médicaments ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Workforce&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Granulomatose avec polyangéite", "description": "Quels traitements sont utilisés pour cette maladie ?\nComment les corticostéroïdes aident-ils ?\nQuels sont les effets secondaires des traitements ?\nLa thérapie biologique est-elle une option ?\nQuelle est l'importance du suivi médical ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Workforce&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Granulomatose avec polyangéite", "description": "Quelles sont les complications possibles ?\nComment l'insuffisance rénale se manifeste-t-elle ?\nLes infections sont-elles fréquentes ?\nQuels problèmes pulmonaires peuvent survenir ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Workforce&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Granulomatose avec polyangéite", "description": "Quels sont les facteurs de risque connus ?\nLe tabagisme augmente-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nL'âge influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Workforce&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la granulomatose avec polyangéite ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, des biopsies et des examens d'imagerie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent la recherche d'anticorps anti-PR3 et des marqueurs d'inflammation." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet d'identifier les granulomes et l'inflammation des vaisseaux." } }, { "@type": "Question", "name": "Quels symptômes cliniques orientent vers cette maladie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs articulaires, des éruptions cutanées et des problèmes respiratoires." } }, { "@type": "Question", "name": "Comment les examens d'imagerie aident-ils au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les examens comme la radiographie ou l'IRM montrent des anomalies dans les poumons et les reins." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de cette maladie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, fièvre, perte de poids, et douleurs musculaires." } }, { "@type": "Question", "name": "La granulomatose affecte-t-elle les voies respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des sinusites, des saignements de nez et des toux persistantes." } }, { "@type": "Question", "name": "Quels problèmes rénaux peuvent survenir ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des atteintes rénales peuvent entraîner une insuffisance rénale et des urines anormales." } }, { "@type": "Question", "name": "Y a-t-il des manifestations cutanées ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées, des nodules et des ulcères peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Peut-on prévenir la granulomatose avec polyangéite ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical peut aider." } }, { "@type": "Question", "name": "Comment éviter les complications ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement précoce et un suivi régulier permettent de réduire le risque de complications." } }, { "@type": "Question", "name": "Les vaccinations sont-elles recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent être recommandées pour prévenir certaines infections." } }, { "@type": "Question", "name": "Y a-t-il des conseils de mode de vie à suivre ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est conseillé." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains médicaments ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent aggraver la maladie et doivent être évités." } }, { "@type": "Question", "name": "Quels traitements sont utilisés pour cette maladie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation." } }, { "@type": "Question", "name": "Comment les corticostéroïdes aident-ils ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils réduisent l'inflammation et soulagent les symptômes rapidement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux." } }, { "@type": "Question", "name": "La thérapie biologique est-elle une option ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des thérapies biologiques ciblées peuvent être utilisées pour les cas réfractaires." } }, { "@type": "Question", "name": "Quelle est l'importance du suivi médical ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires." } }, { "@type": "Question", "name": "Comment l'insuffisance rénale se manifeste-t-elle ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut se manifester par une diminution de la production d'urine et un gonflement." } }, { "@type": "Question", "name": "Les infections sont-elles fréquentes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients sont plus susceptibles de développer des infections en raison du traitement." } }, { "@type": "Question", "name": "Quels problèmes pulmonaires peuvent survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications pulmonaires peuvent inclure des hémorragies et des nodules pulmonaires." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical étroit et des ajustements de traitement." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque significatif pour cette maladie." } }, { "@type": "Question", "name": "Les infections peuvent-elles déclencher la maladie ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme celles des voies respiratoires, peuvent être des déclencheurs." } }, { "@type": "Question", "name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes atteintes d'autres maladies auto-immunes peuvent avoir un risque accru." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "La maladie est plus fréquente chez les adultes jeunes à moyens, généralement entre 30 et 60 ans." } } ] } ] }

Sources (1657 au total)

Profile of the Oncology Physician Workforce and the Characteristics of Attrition.

To determine the prevalence of attrition and the frequency of transition from a primarily clinical role to an industry-related role among oncology physicians.... We tracked yearly Centers for Medicare & Medicaid Services (CMS) billing between 2015 and 2022 to estimate attrition of oncology physicians. A subanalysis of a random sample of 300 oncologists with fe... Of the 16,870 oncologists who billed to CMS in 2015, 3,558 (21%) had stopped billing by 2022. Among a randomly selected 300 oncologists, we found current employment information for 223 (74%); 78 of th... By 2022, 21% of oncology physicians billing to CMS in 2015 had stopped. 78 of the 300 sampled physicians were found to be working in industry. In total, 1 in 17 oncologists (5%) moved to industry over...

A national survey of the radiotherapy dosimetrist workforce in the UK.

To undertake a national survey of the Radiotherapy Dosimetrist workforce within the UK; examining different attributes and experiences, comparing results with published evidence within the literature.... A national, anonymised survey was undertaken between Dec 2020 and end of Feb 2021; employing a mixed-methods approach and blend of closed, open-ended answer choices and free-text comments. Questions i... A total of 223 individuals responded. Nearly half were trained via therapeutic radiography; approximately, a fifth through a clinical technologist/physics routes. Most (70%) had Dosimetrist in their j... Our survey showed a unique profile of the Radiotherapy Dosimetrist workforce in the UK, with a variety of training routes and statutory registration status. Nearly, a third were not engaged in a CPD s... A novel and unique national survey of Dosimetrists working in Radiotherapy in the UK is presented, leading to new insights into current training routes, registration status, job tasks and CPD engageme...

Steps toward a resilient future nurse workforce.

The psychosocial needs of nursing students are a pressing matter as mental health disorders may affect nursing students' journeys as professional nurses.... Psychological distress and burnout in nurses are threats to worldwide health care, as the stress associated with the COVID-19 pandemic could lead to an unstable future global nurse workforce.... Resiliency training can positively impact nurse stress, mindfulness, and resilience, as resilient nurses are better able to manage their response to stress and adversity which will contribute to posit... Educating faculty on resilience will aid nurse educators to create new student instructional approaches to improve mental health wellness.... Supportive faculty behaviors, self-care techniques, and resilience-building infused throughout the nursing curriculum may promote the effective transitioning of students into practice, providing the n...

Women's contribution to medicine in Bahrain: leadership and workforce.

Women make up a significant proportion of workforce in healthcare. However, they remain underrepresented in leadership positions relating to healthcare for a multitude of reasons: balancing personal a... Data were collected from the Bahraini Ministry of Health, National Health Regulatory Authority, Salmaniya Medical Complex, King Hamad University Hospital, Bahrain Defence Force Royal Medical Services,... The results of the study indicated that leadership positions were mostly held by males in Bahrain (59.4% vs. 40.6%). However, Bahraini males and females equally dominated academic positions. Male phys... This study highlights the increasing trend of women's participation and contribution to medicine in Bahrain. The data indicated continued growth in the number of female medical students and physicians...

CTC service heterogeneity and design of a workforce calculator.

To determine the level of heterogeneity in delivery of computed tomography (CT) colonography services and develop a workforce calculator that accommodates the variation identified.... A national survey, based on the "WHO workforce indicators of staffing need", established activity standards for essential tasks in delivery of the service. From these data a workforce calculator was d... Activity standards were established as mode responses >70%. Service homogeneity was greater in areas where professional standards and guidance were available. The mean service size was 1,101. Did not ... The survey identified benefits of radiographer-led direct booking and reporting. The workforce calculator derived from the survey provides a framework to guide the resourcing of expansion while mainta...

Update and projections for New Zealand's ophthalmology workforce.

The aim of this study was to update and project the growth of ophthalmologists in New Zealand. This will help decision makers better understand the current ophthalmologist workforce and make appropria... Supply and demographics of ophthalmologists in New Zealand were obtained from the Medical Council of New Zealand, Health Workforce New Zealand and Health New Zealand - Te Whatu Ora. Ophthalmology trai... In March 2023, there were 175 practising ophthalmologists in New Zealand. Overall, there were 34.0 ophthalmologists per million population, with 201.4 ophthalmologists per million for those aged ≥65 y... The ratio of ophthalmologists per million population aged ≥65 years is projected to drop by 1.5% annually. To meet the demand of an increasing and ageing population, and RANZCO's goal of 40 ophthalmol...